Induction Therapy with PRA023 in Ulcerative Colitis

What is the Purpose of this Study?

This study focuses on individuals with ulcerative colitis (UC) that has been assessed as being moderate to severe. The purpose of the study is to determine whether an investigational drug called PRA023 is safe and effective in treating UC. PRA023 is a monoclonal antibody (man-made antibodies that act like human antibodies in the immune system) that may reduce inflammation and fibrosis associated with inflammatory bowel disease, such as UC and Crohn’s disease. Participants will be randomly assigned to received either PRA023 or placebo (inactive substance).


Eligibility

  • * Confirmed diagnosis of ulcerative colitis (UC)
  • * Has moderately to severely active UC as defined by 3-component Modified Mayo score
Show more

Where can I participate?

Beverly

More about this Clinical Trial

What is the full name of this clinical trial?

A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Induction Therapy with PRA023 in Subjects with Moderately to Severely Active Ulcerative Colitis

Study Details
Disease Type/Condition

Other

Principal Investigator

Melmed, Gil

Co-Investigators

Andrea Banty, Susie Lee

Age Group

Adult

Phase

II

IRB Number

STUDY00001598

ClinicalTrials.gov ID

NCT04996797

Key Eligibility
ClinicalTrials.gov

How do I learn more about this study?
Email
clinicaltrials@cshs.org
Study Detail
Disease Type/Condition

Other

Principal Investigator

Melmed, Gil

Age Group

Adult

Phase

II

IRB Number

PR200-102

ClinicalTrials.gov ID

NCT04996797

Key Eligibility
ClinicalTrials.gov

Contact
Email
clinicaltrials@cshs.org